Immune Checkpoint Inhibitors in Hodgkin Lymphoma

Sort by:
Relevance Thumbs Up Comments Views Newest Oldest
16:08

John Kuruvilla

KEYNOTE-204 in R/R cHL: How Does This Trial Influence Our Practice?

  • 99 views
  • March 11, 2022
17:03

Stephen M. Ansell

PD-1 Blockade in Hodgkin Lymphoma: Moving Up the Ranks

  • 216 views
  • March 5, 2022
14:45

SOHO 3rd Italian Conference

SOHO Italy 2021: How I Manage Hodgkin Lymphoma in the USA

FEATURING Amanda Cashen
  • 23 views
  • December 23, 2021
16:55

Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

SOHO 2021 on Hodgkin Lymphoma: What to Do When Checkpoint Inhibitors Fail

FEATURING Philippe Armand
  • 20 views
  • September 23, 2021
12:15

Tatyana Feldman

Incorporating Novel Agents in 1L Therapy for Advanced cHL: PFS Data for Brentuximab Vedotin + AVD vs. ABVD, Efficacy Data for Nivo & Pembro Mono, and Nivo Combinations

  • 137 views
  • May 3, 2021
  • 1
20:13

UAB Hematology Review 2021

Advanced Stage cHL: Considering Frontline, Secondary, and Salvage Treatment Choices and Navigating End of Treatment PET and PET2+ Patients

FEATURING Gaurav Goyal
  • 38 views
  • March 18, 2021
07:31

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on cHL: 2L Pembro + GVD, Brentuximab Vedotin & Checkpoint Blockade Combination in High Risk Patients

FEATURING Peter Riedell
  • 124 views
  • March 5, 2021
10:50

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

ASH Updates on R/R cHL: How to Consider Pembro-GVH? What Is the Role of Radiation-Based Approaches? What Is the Feasibility of Targeting Multiple Pathways for Patients With Relapses?

FEATURING Jakub Svoboda
  • 97 views
  • March 5, 2021
09:24

SOHO Highlights: State of the Art and Next Questions

ECHELON-1 Data on Brentuximab Vedotin for Frontline Advanced cHL: Examining A+AVD vs. ABVD

FEATURING David Straus
  • 293 views
  • February 23, 2021
  • 1
11:39

SOHO Highlights: State of the Art and Next Questions

Early Stage cHL Management: Bulky vs. Non-bulky Disease, Better Chemotherapy Options to Improve PFS

FEATURING David Straus
  • 174 views
  • February 3, 2021
15:16

2nd SOHO Italian Conference

Updates on HL: Pembro Mono in Untreated Patients, Brentuximab Vedotin + Nivo Combo in Older Population, the Use of Anti-CD30 CAR-T in R/R Disease

FEATURING Antonello Pinto
  • 120 views
  • January 27, 2021
  • 1
15:40

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

IO for R/R cHL: Optimal Treatment Regimen, Therapy Duration & Discontinuation, Prognostic Factors, Treatment Strategy in Case of Resistance

FEATURING Kirill Lepik
  • 22 views
  • January 12, 2021
09:59

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on R/R cHL: Can We Improve Chemo With ADCs and CPI? Is Toxicity Excessive Compared to Standard Regimens?

FEATURING David Straus
  • 58 views
  • October 30, 2020
15:55

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

R/R HL Updates: What Are Frontline Therapeutic Choices and How Can We Integrate Novel Agents? What Combinations Can Help Overcome Resistance and PD-1 Blockade?

FEATURING Alex Herrera
  • 148 views
  • October 30, 2020
06:14

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on R/R cHL: Does Pembro Show Any PFS Improvement Compared to BV?

FEATURING Luis Fayad
  • 64 views
  • October 12, 2020
05:43

John Kuruvilla

Key Efficacy and Safety Findings of the KEYNOTE-204 Study in R/R cHL: Comparing Pembro and BV

  • 145 views
  • September 30, 2020
  • 1
23:29

7th Eurasian Hematology Oncology Summit

2020 Update on IO in R/R cHL: Is Long-Term Therapy w/ Nivo Feasible and Safe?

FEATURING Tulin Tuglular
  • 138 views
  • September 30, 2020
  • 1
15:27

7th Eurasian Hematology Oncology Summit

How I Treat HL in 2020: What Is the Role of PET-Adapted Strategies? Is BV Superior to Immune CPIs in R/R Disease?

FEATURING Christian Gisselbrecht
  • 200 views
  • September 30, 2020
09:41

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on R/R Hodgkin Lymphoma: Can We Consider Pembrolizumab a New SoC?

FEATURING William Hammond
  • 154 views
  • August 25, 2020
04:36

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Hodgkin Lymphoma: Is Pembrolizumab a Better Option Than Brentuximab in R/R Hodgkin Patients Post ASCT Or Ineligible for ASCT?

FEATURING Manali Kamdar
  • 30 views
  • August 24, 2020
09:23

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Hodgkin Lymphoma: Pembro vs. Brentuximab Vedotin in Late Stage Disease - Which Option is Superior?

FEATURING David Maloney
  • 150 views
  • August 19, 2020
  • 1
06:05

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Classical Hodgkin Lymphoma: Does Pembrolizumab Improve PFS vs. Brentuximab Vedotin in Patients With Relapsed/Refractory Disease?

FEATURING Jakub Svoboda
  • 140 views
  • August 6, 2020
03:26

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Hodgkin Lymphoma: PD-1 mAb or Brentuximab Vedotin - Which Is the First Option for R/R HL?

FEATURING Jake Soumerai
  • 16 views
  • July 27, 2020
08:30

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Lymphomas: Brentuximab Vedotin vs. Pembrolizumab - Which Single Agent Should You Pick First for R/R cHL?

FEATURING Neha Mehta-Shah
  • 400 views
  • July 22, 2020
  • 4
12:24

Penn Medicine 2020 Updates in Oncology

2020 ASCO Update on Lymphomas: Should Pembro Be New SoC in R/R cHL? Is Axicabtagene Ciloleucel Effective and Durable in R/R Indolent Non-Hodgkin Lymphoma?

FEATURING James Gerson
  • 251 views
  • July 22, 2020
  • 2

Immune Checkpoint Inhibitors in Hodgkin Lymphoma

No subtopics